LP-310 shows significant improvements in pain and inflammation for oral lichen planus, with favorable safety results in Phase 2a trial. Lipella Pharmaceuticals has announced promising results from ...
Hosted on MSN1mon
FDA approves Lipella's oral treatment access programThe EAP will provide patients with oral lichen planus (OLP), a chronic inflammatory condition of the mouth's mucous membranes, access to LP-310 outside of clinical trials. According to ...
Morningstar brands and products Company Portfolio ...
LP-310 is an innovative, localized therapy formulated to provide targeted relief for oral lichen planus patients while minimizing systemic exposure. Oral lichen planus is a chronic inflammatory ...
All Penny Stocks (English) on MSN1mon
Biotech Rips On Topline AnalysisA biotech company is turning heads so far during Tuesday’s session after it shared topline analysis of its Phase 2a dose-ranging trial of LP-310, a liposomal-tacrolimus oral rinse formulation of ...
LP-310 Treatment Demonstrates Clinically Meaningful Reductions in Pain, Ulceration, and Inflammation Across All Key Metrics Findings Highlight Favorable Safety Profile and Tolerability of Twice ...
LP-310 demonstrated a strong safety profile, with no product-related serious adverse events (SAEs) and no patient dropouts. The trial showed statistically significant improvements across multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback